ChAdOx1 nCoV-19 vaccine for SARS-CoV-2

alwin shared this article with you from Inoreader [Correspondence] ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 Via The Lancet The ChAdOx1 nCoV-19 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), described by Pedro Folegatti and colleagues,1 was an important milestone in vaccine development to contain the ongoing pandemic. The vaccine is one of several SARS-CoV-2 vaccines that have entered the human trial phase, and the phase 1/2 trial showed encouraging results. This trial has focused on the most relevant clinical outcomes of safety, reactogenicity, and immunogenicity of the vaccine. The recruited participants (ie, healthy adults aged 18–55 years who were negative for SARS-CoV-2) were randomly assigned to receive either the vaccine (ie, ChAdOx1 nCoV-19 at a dose of 5 × 104 viral particles) or an active control (ie, a meningococcal conjugate vaccine; MenACWY) as a single intramuscular injection. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.